+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Mirabegron Drugs Market - Global Forecast 2026-2032- Product Image
Mirabegron Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Mirabegron Drugs Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6131146
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Mirabegron Drugs Market is projected to reach USD 1.44 Billion in 2026. It is expected to continue growing at a CAGR of 4.94%, reaching USD 1.93 Billion by 2032.

Mirabegron Drugs: Executive Summary and Market Context

Mirabegron is a beta-3 adrenergic receptor agonist used primarily to manage symptoms associated with overactive bladder, including urgency, increased urinary frequency, and urge urinary incontinence. Its therapeutic value is linked to bladder-relaxation effects and an alternative mechanism to antimuscarinic medicines. The market is shaped by clinical practice patterns, regulatory requirements, reimbursement conditions, patient adherence, and competition among pharmacological and nonpharmacological treatment options.

Treatment Shifts Reshaping the Mirabegron Landscape

The treatment landscape is shifting toward individualized overactive-bladder management. Clinicians increasingly weigh symptom burden, age, comorbidities, blood-pressure considerations, cognitive risk, tolerability, and prior treatment response when selecting therapy. Combination regimens, switching strategies, extended-release dosing, generic availability, and broader attention to persistence are influencing prescribing decisions. Diagnosis and care are also being supported by bladder diaries, remote consultations, pelvic-floor interventions, behavioral modification, and follow-up focused on real-world treatment response.

Artificial Intelligence’s Cumulative Role in Mirabegron Care

Artificial intelligence can contribute across the care pathway without replacing clinical judgment. Potential applications include identifying symptom patterns in electronic records, supporting differential assessment, predicting persistence or discontinuation risk, and helping clinicians personalize follow-up. AI-enabled analysis of patient-reported outcomes may improve recognition of inadequate response and adverse effects. However, responsible use requires representative data, clinical validation, privacy safeguards, explainability, and controls against biased recommendations, particularly where access to specialist urological care is uneven.

Regional Insights Across Six Diverse Care Environments

North America is characterized by established diagnostic pathways, specialist access, and payer scrutiny around prescription selection and persistence. Europe combines mature healthcare systems with country-specific reimbursement and health-technology-assessment requirements. Asia-Pacific presents substantial variation in regulatory systems, urbanization, diagnosis rates, and access to branded and generic therapies. Latin America is influenced by public-private healthcare differences, affordability, and uneven specialist coverage. The Middle East shows a mix of advanced urban care and access disparities across health systems. Africa faces greater constraints related to diagnosis, specialist availability, procurement, and continuity of treatment, making awareness and primary-care integration especially important.

Group-Level Signals Across ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets reflect diverse regulatory standards, income levels, and healthcare capacity, creating different routes to diagnosis and medicine access. BRICS members span large and contrasting populations, with domestic manufacturing, reimbursement design, and public procurement playing important roles. The European Union benefits from regulatory coordination while retaining national differences in pricing and reimbursement. G7 systems generally have stronger evidence infrastructure and pharmacovigilance capabilities, alongside demanding value assessments. GCC countries often combine well-resourced urban facilities with centralized purchasing and cross-border care patterns. NATO membership is not a healthcare market category, but the group includes countries with varied pharmaceutical systems, regulatory approaches, and public-health priorities.

Country-Level Considerations for Mirabegron Access and Use

Australia and Canada combine structured reimbursement processes with geographically uneven specialist access. Brazil, Mexico, and Russia reflect large territories and varied public-private pathways, making affordability, procurement, and regional availability important. China and India have broad manufacturing and healthcare ecosystems, but access and prescribing can differ substantially between metropolitan and rural settings. Japan and South Korea have mature clinical infrastructure and aging populations, with local reimbursement and prescribing practices shaping uptake. France, Germany, Italy, Spain, and the United Kingdom operate within sophisticated European systems, yet differ in assessment procedures, formularies, primary-care roles, and regional implementation. The United States is influenced by payer formularies, utilization management, specialist care, and patient out-of-pocket exposure.

Actions for Leaders: Improve Evidence, Access, and Patient Persistence

Industry leaders should prioritize evidence that reflects routine clinical practice, including comparative tolerability, persistence, quality-of-life outcomes, and use in patients with relevant comorbidities. Access strategies should be tailored to national reimbursement rules and should support appropriate diagnosis rather than indiscriminate treatment. Clear education for clinicians and patients can reinforce blood-pressure considerations, dosing expectations, adherence, and follow-up. Partnerships with providers should strengthen symptom assessment and referral pathways, while digital tools should be implemented with robust privacy, clinical validation, and human oversight. Supply resilience, pharmacovigilance, and transparent medical communication should remain core operating priorities.

Research Methodology for the Mirabegron Drugs Executive Summary

This executive summary uses a structured qualitative assessment of mirabegron’s therapeutic role and the factors that influence its use across healthcare systems. The framework considers mechanism of action, treatment pathways, clinical decision criteria, regulatory and reimbursement environments, demographic and disease-management conditions, access to care, and digital-health developments. Regional, group, and country comparisons are presented as contextual insights rather than quantitative market measurements. Claims are limited to established healthcare and pharmaceutical considerations, and no market estimates, shares, forecasts, or company-specific assessments are included.

Conclusion: Positioning Mirabegron Within Evolving Bladder Care

Mirabegron remains relevant to overactive-bladder treatment because it offers a distinct pharmacological approach and can support individualized care when treatment benefits, risks, and patient preferences are considered together. Its future role will depend less on a single global pattern than on local diagnosis, reimbursement, clinical confidence, affordability, and persistence. Leaders that combine credible outcomes evidence with responsible access programs, resilient supply, and patient-centered follow-up will be better positioned to support appropriate use across diverse healthcare environments.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Mirabegron Drugs Market, by Indication
7.1. Introduction
7.2. Idiopathic
7.3. Neurogenic
8. Mirabegron Drugs Market, by Therapy Type
8.1. Introduction
8.2. Combination Therapy
8.2.1. With Alpha-Blocker
8.2.2. With Antimuscarinic
8.3. Monotherapy
9. Mirabegron Drugs Market, by Formulation
9.1. Introduction
9.2. Extended-Release Tablet
9.3. Granules For Oral Suspension
10. Mirabegron Drugs Market, by Dosage Strength
10.1. Introduction
10.2. 25 mg Tablet
10.3. 50 mg Tablet
11. Mirabegron Drugs Market, by Product Type
11.1. Introduction
11.2. Branded
11.3. Generic
12. Mirabegron Drugs Market, by Age Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
13. Mirabegron Drugs Market, by Packaging
13.1. Introduction
13.2. Oral Suspension
13.3. Tablets
13.3.1. Blister Pack
13.3.2. Bottle
14. Mirabegron Drugs Market, by Distribution Channel
14.1. Introduction
14.2. Hospital Pharmacy
14.2.1. Government Hospital
14.2.2. Private Hospital
14.3. Online Pharmacy
14.4. Retail Pharmacy
14.4.1. Chain Pharmacy
14.4.2. Independent Pharmacy
15. Mirabegron Drugs Market, by End User
15.1. Introduction
15.2. Clinic
15.3. Home Care
15.4. Hospital
16. Mirabegron Drugs Market, by Region
16.1. Introduction
16.2. Asia-Pacific
16.3. Europe
16.4. North America
16.5. Latin America
16.6. Africa
16.7. Middle East
17. Mirabegron Drugs Market, by Group
17.1. Introduction
17.2. NATO
17.3. G7
17.4. European Union
17.5. BRICS
17.6. ASEAN
17.7. GCC
18. Mirabegron Drugs Market, by Country
18.1. Introduction
18.2. United States
18.3. China
18.4. Germany
18.5. Japan
18.6. India
18.7. United Kingdom
18.8. France
18.9. Canada
18.10. Australia
18.11. Italy
18.12. South Korea
18.13. Brazil
18.14. Russia
18.15. Mexico
18.16. Spain
19. Competitive Landscape
19.1. Market Share Analysis, 2025
19.2. Market Concentration Analysis, 2025
19.2.1. Concentration Ratio (CR)
19.2.2. Herfindahl Hirschman Index (HHI)
19.3. Recent Developments & Impact Analysis, 2025
19.4. Product Portfolio Analysis, 2025
19.5. Benchmarking Analysis, 2025
20. Company Profiles
20.1. Ajanta Pharma Limited
20.2. Alembic Pharmaceuticals Ltd
20.3. Alkem Laboratories Ltd.
20.4. Astellas Pharma Inc.
20.5. Cipla Ltd.
20.6. Dr. Reddy’s Laboratories Limited
20.7. Eskayef Pharmaceuticals Limited
20.8. Glenmark Pharmaceuticals Limited
20.9. Intas Pharmaceuticals Ltd
20.10. Ipca Laboratories Ltd
20.11. Lupin Limited
20.12. Minakem SAS
20.13. MSN Laboratories Private Limited
20.14. Neuland Laboratories Ltd.
20.15. Sandoz AG
20.16. STERIS HEALTHCARE PVT LTD
20.17. Strides Pharma Science Limited
20.18. Sun Pharmaceutical Industries Ltd.
20.19. Zydus Lifesciences Limited
21. Key Experts
LIST OF FIGURES
FIGURE 1. Global Mirabegron Drugs Market, Years Considered for the Study
FIGURE 2. Global Mirabegron Drugs Market, Research Design
FIGURE 3. Global Mirabegron Drugs Market, Research Framework
FIGURE 4. Global Mirabegron Drugs Market, Data Triangulation
FIGURE 5. Global Mirabegron Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Mirabegron Drugs Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Mirabegron Drugs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Mirabegron Drugs Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 9. Global Mirabegron Drugs Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Mirabegron Drugs Market Size, by Formulation, 2025 vs 2032 (%)
FIGURE 11. Global Mirabegron Drugs Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Mirabegron Drugs Market Size, by Dosage Strength, 2025 vs 2032 (%)
FIGURE 13. Global Mirabegron Drugs Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Mirabegron Drugs Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 15. Global Mirabegron Drugs Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Mirabegron Drugs Market Size, by Age Group, 2025 vs 2032 (%)
FIGURE 17. Global Mirabegron Drugs Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Mirabegron Drugs Market Size, by Packaging, 2025 vs 2032 (%)
FIGURE 19. Global Mirabegron Drugs Market Size, by Packaging, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Mirabegron Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 21. Global Mirabegron Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Mirabegron Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 23. Global Mirabegron Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 24. Global Mirabegron Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 25. Global Mirabegron Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 26. Global Mirabegron Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 27. Global Mirabegron Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 28. Global Mirabegron Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 29. Global Mirabegron Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Mirabegron Drugs Market Segmentation & Coverage
TABLE 2. Global Mirabegron Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Idiopathic Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Idiopathic Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Idiopathic Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Neurogenic Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Neurogenic Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Neurogenic Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 11. Global Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Combination Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global With Alpha-Blocker Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global With Alpha-Blocker Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global With Alpha-Blocker Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global With Antimuscarinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global With Antimuscarinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global With Antimuscarinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Monotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Monotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Monotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 24. Global Extended-Release Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Extended-Release Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Extended-Release Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Granules For Oral Suspension Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Granules For Oral Suspension Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Granules For Oral Suspension Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 31. Global 25 mg Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global 25 mg Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global 25 mg Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global 50 mg Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global 50 mg Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global 50 mg Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 38. Global Branded Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Branded Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Branded Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 45. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 55. Global Oral Suspension Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Oral Suspension Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Oral Suspension Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Blister Pack Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Blister Pack Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Blister Pack Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Bottle Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Bottle Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Bottle Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 68. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Government Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Government Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Government Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Private Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Private Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Private Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Chain Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Chain Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Chain Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Independent Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Independent Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Independent Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. Global Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Mirabegron Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific Mirabegron Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Asia-Pacific Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. Europe Mirabegron Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Europe Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 116. Europe Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 117. Europe Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 118. Europe Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 119. Europe Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 120. Europe Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 121. Europe Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 122. Europe Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 123. Europe Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 124. Europe Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 125. Europe Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 126. Europe Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 127. Europe Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. North America Mirabegron Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. North America Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 130. North America Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 131. North America Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 132. North America Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 133. North America Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 134. North America Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 135. North America Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 136. North America Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 137. North America Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 138. North America Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. North America Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 140. North America Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 141. North America Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 142. Latin America Mirabegron Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 143. Latin America Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 144. Latin America Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 145. Latin America Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 146. Latin America Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 147. Latin America Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 148. Latin America Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 149. Latin America Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 150. Latin America Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 151. Latin America Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 152. Latin America Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. Latin America Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 154. Latin America Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 155. Latin America Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. Africa Mirabegron Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 157. Africa Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 158. Africa Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 159. Africa Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 160. Africa Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 161. Africa Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 162. Africa Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 163. Africa Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 164. Africa Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 165. Africa Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 166. Africa Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. Africa Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 168. Africa Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 169. Africa Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. Middle East Mirabegron Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 171. Middle East Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 172. Middle East Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 173. Middle East Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 174. Middle East Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 175. Middle East Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 176. Middle East Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 177. Middle East Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 178. Middle East Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 179. Middle East Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 180. Middle East Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. Middle East Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 182. Middle East Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 183. Middle East Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. Global Mirabegron Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 185. NATO Mirabegron Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 186. NATO Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 187. NATO Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 188. NATO Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 189. NATO Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 190. NATO Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 191. NATO Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 192. NATO Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 193. NATO Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 194. NATO Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 195. NATO Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. NATO Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 197. NATO Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 198. NATO Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. G7 Mirabegron Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 200. G7 Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 201. G7 Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 202. G7 Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 203. G7 Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 204. G7 Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 205. G7 Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 206. G7 Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 207. G7 Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 208. G7 Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 209. G7 Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. G7 Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 211. G7 Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 212. G7 Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 213. European Union Mirabegron Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 214. European Union Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 215. European Union Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 216. European Union Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 217. European Union Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 218. European Union Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 219. European Union Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 220. European Union Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 221. European Union Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 222. European Union Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 223. European Union Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 224. European Union Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 225. European Union Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 226. European Union Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. BRICS Mirabegron Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 228. BRICS Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 229. BRICS Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 230. BRICS Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 231. BRICS Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 232. BRICS Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 233. BRICS Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 234. BRICS Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 235. BRICS Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 236. BRICS Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 237. BRICS Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 238. BRICS Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 239. BRICS Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 240. BRICS Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 241. ASEAN Mirabegron Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 242. ASEAN Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 243. ASEAN Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 244. ASEAN Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 245. ASEAN Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 246. ASEAN Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 247. ASEAN Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 248. ASEAN Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 249. ASEAN Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 250. ASEAN Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 251. ASEAN Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. ASEAN Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 253. ASEAN Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 254. ASEAN Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 255. GCC Mirabegron Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 256. GCC Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 257. GCC Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 258. GCC Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 259. GCC Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 260. GCC Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 261. GCC Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 262. GCC Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 263. GCC Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 264. GCC Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 265. GCC Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 266. GCC Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 267. GCC Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 268. GCC Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 269. Global Mirabegron Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 270. United States Mirabegron Drugs Market Size, 2017-2032 (USD Million)
TABLE 271. United States Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 272. United States Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 273. United States Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 274. United States Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 275. United States Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 276. United States Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 277. United States Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 278. United States Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 279. United States Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 280. United States Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 281. United States Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 282. United States Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 283. United States Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 284. China Mirabegron Drugs Market Size, 2017-2032 (USD Million)
TABLE 285. China Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 286. China Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 287. China Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 288. China Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 289. China Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 290. China Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 291. China Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 292. China Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 293. China Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 294. China Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 295. China Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 296. China Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 297. China Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 298. Germany Mirabegron Drugs Market Size, 2017-2032 (USD Million)
TABLE 299. Germany Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 300. Germany Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 301. Germany Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 302. Germany Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 303. Germany Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 304. Germany Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 305. Germany Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 306. Germany Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 307. Germany Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 308. Germany Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 309. Germany Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 310. Germany Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 311. Germany Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 312. Japan Mirabegron Drugs Market Size, 2017-2032 (USD Million)
TABLE 313. Japan Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 314. Japan Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 315. Japan Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 316. Japan Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 317. Japan Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 318. Japan Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 319. Japan Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 320. Japan Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 321. Japan Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 322. Japan Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 323. Japan Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 324. Japan Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 325. Japan Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 326. India Mirabegron Drugs Market Size, 2017-2032 (USD Million)
TABLE 327. India Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 328. India Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 329. India Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 330. India Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 331. India Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 332. India Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 333. India Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 334. India Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 335. India Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 336. India Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 337. India Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 338. India Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 339. India Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 340. United Kingdom Mirabegron Drugs Market Size, 2017-2032 (USD Million)
TABLE 341. United Kingdom Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 342. United Kingdom Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 343. United Kingdom Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 344. United Kingdom Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 345. United Kingdom Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 346. United Kingdom Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 347. United Kingdom Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 348. United Kingdom Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 349. United Kingdom Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 350. United Kingdom Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 351. United Kingdom Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 352. United Kingdom Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 353. United Kingdom Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 354. France Mirabegron Drugs Market Size, 2017-2032 (USD Million)
TABLE 355. France Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 356. France Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 357. France Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 358. France Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 359. France Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 360. France Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 361. France Mirabegron Drugs Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 362. France Mirabegron Drugs Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 363. France Mirabegron Drugs Market Size, by Tablets, 2017-2032 (USD Million)
TABLE 364. France Mirabegron Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 365. France Mirabegron Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 366. France Mirabegron Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 367. France Mirabegron Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 368. Canada Mirabegron Drugs Market Size, 2017-2032 (USD Million)
TABLE 369. Canada Mirabegron Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 370. Canada Mirabegron Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 371. Canada Mirabegron Drugs Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 372. Canada Mirabegron Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 373. Canada Mirabegron Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 374. Canada Mirabegron Drugs Market Size, by Product Type, 2017-2032 (USD M

Companies Mentioned

  • Ajanta Pharma Limited
  • Alembic Pharmaceuticals Ltd
  • Alkem Laboratories Ltd.
  • Astellas Pharma Inc.
  • Cipla Ltd.
  • Dr. Reddy’s Laboratories Limited
  • Eskayef Pharmaceuticals Limited
  • Glenmark Pharmaceuticals Limited
  • Intas Pharmaceuticals Ltd
  • Ipca Laboratories Ltd
  • Lupin Limited
  • Minakem SAS
  • MSN Laboratories Private Limited
  • Neuland Laboratories Ltd.
  • Sandoz AG
  • STERIS HEALTHCARE PVT LTD
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited

Related Topics

Related Reports

Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report - Product Image

Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Overactive Bladder Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Overactive Bladder Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 130 Pages
  • Global
From
Medicine for Urge Incontinence Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Medicine for Urge Incontinence Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Overactive Bladder Treatment Market Report 2026 - Product Image

Overactive Bladder Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Overactive Bladder Treatment Market - Global Forecast 2026-2032 - Product Image

Overactive Bladder Treatment Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.